Zurich, Feb 7, 2026, 21:45 CET — Market’s last trades are in.
- Nestle shares ended Friday up 0.6%, outpacing the Swiss blue-chip index.
- Investors are entering the week with their attention on the ongoing infant formula recalls across Europe.
- Nestle is set to report its full-year results on Feb. 19.
Nestle ended Friday’s session 0.6% higher at 78.89 Swiss francs, just edging out the SMI blue-chip index’s modest rise. 1
The world’s largest packaged food company lands squarely back in the spotlight this week, as investors juggle two immediate concerns: an expanding infant formula recall across parts of Europe, and the approach of Nestle’s annual results.
Shares remain far under last year’s peak. Traders aren’t hesitating—any whiff of margin squeeze, regulatory snag, or changing consumer appetite sparks a swift move.
Nestle shares moved in a range from 77.72 to 79.33 francs on Friday, with around 2.56 million shares traded, exchange data showed. 2
That tone lifted markets across the board. After a choppy week, global equities snapped higher on Friday, risk appetite snapping back. Wall Street rallied hard. 3
Even so, baby formula remains in the spotlight. Danone has widened its recalls throughout Europe after hitting an EU-imposed ceiling for the cereulide toxin—known to trigger nausea and vomiting. Other formula makers, like Nestle, have also gotten caught up in the fallout. French officials, for their part, are investigating whether batches of recalled Guigoz formula are tied to two infant deaths; findings are expected within days. 4
Nestle hasn’t confirmed several of the official figures mentioned earlier during the recall, and says its own internal threshold is tougher than what the EU recommends.
Danone shares slid as much as 3.2% in Paris on Friday, after news that the recall had widened—a sharp signal of just how fast food safety worries can rattle the sector.
Next up for Nestle: full-year results drop on Feb. 19, and management will brief analysts and investors at 0900 CET. 5
Investors want to hear how much of sales growth is being driven by pricing rather than volume, and they’ll be watching for any updates on costs or clues about how fast savings are building up.
Still, there’s a risk here: If the formula probe or recall ends up being broader than expected, that could spell trouble. More products pulled, stricter rules at the national level, or another wave of customer pushback would likely drag out the clean-up and drive up expenses.
Monday’s session brings attention to any developments over the weekend regarding the recall, with traders eyeing potential statements from French officials. The next significant date circled on the calendar: Feb. 19.
